Advertisement

Topics

NHS England seals access deals with big pharma for breast cancer and MS

06:00 EST 9 Nov 2017 | Pharmafile

NHS England has entered into a commercial agreement with MSD which aims to provide access to innovative treatments for both multiple sclerosis and breast cancer, it has emerged. As part of the agreement with two major pharma firms, Merck’s multiple sclerosis treatment Mavenclad (cladribine tablets) will be made available to hundreds of patients effective 10 November, while an agreement in principle has been reached on the availability of Roche’s Perjeta (pertuzumab) by unlocking the final stage of NICE’s appraisal. 

read more

Original Article: NHS England seals access deals with big pharma for breast cancer and MS

NEXT ARTICLE

More From BioPortfolio on "NHS England seals access deals with big pharma for breast cancer and MS"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...